A phase 3, multi-center trial of oral, sustained-release fampridine (4-aminopyridine) in multiple sclerosis

被引：0
|
作者：
Goodman, Andrew
Schwid, Steven
Brown, Theodore
Krupp, Lauren
Schapiro, Randall
Marinucci, Lawrence
Cohen, Ron
Blight, Andrew
机构：
来源：
NEUROLOGY | 2007年 / 68卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：A206 / A206
页数：1
相关论文
共 50 条
  • [21] Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine)
    Keune, Philipp M.
    Cocks, Adam J.
    Young, William R.
    Burschka, Janina M.
    Hansen, Sascha
    Hofstadt-van Oy, Ulrich
    Oschmann, Patrick
    Muenssinger, Jana
    BMC NEUROLOGY, 2015, 15
  • [22] Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine)
    Philipp M. Keune
    Adam J. Cocks
    William R. Young
    Janina M. Burschka
    Sascha Hansen
    Ulrich Hofstadt-van Oy
    Patrick Oschmann
    Jana Muenssinger
    BMC Neurology, 15
  • [23] Randomized double-blind crossover trial of fampridine-SR (sustained release 4-aminopyridine) in patients with incomplete spinal cord injury
    Potter, PJ
    Hayes, KC
    Segal, JL
    Hsieh, JTC
    Brunnemann, SR
    Delaney, GA
    Tierney, DS
    Mason, D
    JOURNAL OF NEUROTRAUMA, 1998, 15 (10) : 837 - 849
  • [24] Pharmacokinetics of an immediate-release oral formulation of fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury
    Hayes, KC
    Katz, MA
    Devane, JG
    Hsieh, JTC
    Wolfe, DL
    Potter, RJ
    Blight, AR
    JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (04): : 379 - 385
  • [25] Sustained release oral fampridine in the treatment of multiple sclerosis (vol 10, pg 2025, 2009)
    Kachuck, N.
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (14) : 2393 - 2393
  • [26] Pharmacokinetics and Tolerability of Single Escalating Doses of Fampridine Sustained-Release Tablets in Patients With Multiple Sclerosis: A Phase I-II, Open-Label Trial
    Vollmer, Timothy
    Henney, Herbert R., III
    CLINICAL THERAPEUTICS, 2009, 31 (10) : 2206 - 2214
  • [27] A Phase 3 Trial of Extended Release Oral Dalfampridine in Multiple Sclerosis
    Goodman, Andrew D.
    Brown, Theodore R.
    Edwards, Keith R.
    Krupp, Lauren B.
    Schapiro, Randall T.
    Cohen, Ron
    Marinucci, Lawrence N.
    Blight, Andrew R.
    ANNALS OF NEUROLOGY, 2010, 68 (04) : 494 - 502
  • [28] THE PHARMACOKINETICS AND TOLERABILITY OF A SLOW-RELEASE FORMULATION OF 4-AMINOPYRIDINE IN MULTIPLE-SCLEROSIS PATIENTS
    BEVER, CT
    YOUNG, D
    TIERNEY, D
    CONWAY, K
    KATZ, E
    COSTELLO, K
    FOSSLER, M
    JOHNSON, KP
    NEUROLOGY, 1995, 45 (04) : A351 - A351
  • [29] Lercanidipine hydrochloride versus felodipine sustained-release for mild-to-moderate hypertension: a multi-center, randomized clinical trial
    Wu, Ying
    Xu, Mengdan
    Wang, Hao
    Xu, Xin
    Zhao, Shuiping
    Zhang, Mei
    Jin, Huigen
    Yan, Jinchuan
    Wang, Bangning
    Gong, Jianbin
    Lu, Xiang
    Peng, Jianqiang
    Dai, Qiuyan
    CURRENT MEDICAL RESEARCH AND OPINION, 2015, 31 (01) : 171 - 176
  • [30] Twice-daily fampridine-SR (sustained-release 4-aminopyridine): Safety and early efficacy experience in 150 patients with chronic motor-incomplete spinal cord injury
    Jackson, AB
    Ditunno, JF
    Lammertse, DP
    Graziani, V
    ANNALS OF NEUROLOGY, 2002, 52 (03) : S88 - S88
12345